Abstract:BACKGROUND:Terbinafine and itraconazole are the common antifungal drugs in clinic. In vitro experiments proved that terbinafine combined with itraconazole achieves better antifungal effects. However, clinical study addressing this issue was still scarce.STUDY QUESTION:Terbinafine combined with itraconazole achieves better therapeutic effects in fungal skin diseases.STUDY DESIGN:Approximately 178 patients with fungal skin diseases from Meizhou People's Hospital, China, between October 2016 and October 2017 were admitted to this study. Patients were randomly distributed to 3 groups by randomly selecting random numbers and were treated with terbinafine, itraconazole, monotherapy, or combined therapy. Both patients and study investigators were unaware of grouping situations during experiments. Fifteen patients were excluded due to poor compliance, and 11 patients were excluded due to incomplete data. Finally, 152 patients were analyzed for this study.MEASURES AND OUTCOMES:The therapeutic effects were evaluated by clinic symptom scores, mycology examination, the cure rate, and the cure time. Adverse events, relapse of disease, and patient's satisfaction level were recorded during follow-up.RESULTS:In the terbinafine + itraconazole group, at 14 days after treatment, the symptom scores were significantly decreased, compared with the terbinafine or itraconazole group (P1 < 0.05, P2 < 0.05). At 28 days after treatment, the fungal infection of 37 patients was eradicated, which were significantly more than 26 patients in the terbinafine group and 19 patients in the itraconazole group (P1 < 0.05, P2 < 0.05). The terbinafine + itraconazole group also exhibited 100% cure rate of patients with fungal skin diseases, shorter cure time, and increased number of cured patients during the same treatment period, which was better than terbinafine or itraconazole monotherapy (P1 < 0.05, P2 < 0.05). In addition, no adverse events and no relapse of fungal disease were reported in the terbinafine + itraconazole group during follow-up. Ninety-eight percent patients were satisfied with the therapeutic effects of combined treatment.CONCLUSIONS:Compared with terbinafine or itraconazole monotherapy, terbinafine + itraconazole combined treatment achieves better therapeutic effects in fungal skin diseases.

Activities of Terbinafine in Combination with Itraconazole and Fluconazole Against Isolates of Candida albicans In Vitro

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles

In vitro activity of terbinafine in combinations with other antifungi drugs against clinical pathogenic fungi of vulvovaginal candidiasis

Susceptibility Testing of the Combination of Itraconazole and Terbinafine in Vitro

In vitro susceptibility testing of the combination of terbinafine and itraconazole against dematiaceous fungi

In Vitro Interaction of Terbinafine with Itraconazole and Amphotericin B Against Fungi Causing Chromoblastomycosis in China.

Combination of itraconazole and terbinafine in treating sporotrichosis and their in vitro antifungal activities against Sporothrix schenckii

In vitro activity of itraconazole in combination with terbinafine against clinical strains of itraconazole-insensitive Sporothrix schenckii.

Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora.

In Vitro Testing of Amorolfine in Combination with Terbinafine and Itraconazone Against Fungal Isolates in Onychomycosis

In Vitro Interactions Between Tacrolimus and Azoles Against Candida Albicans Determined by Different Methods.

In vitro determination of the combination of ciclopirox and terbinafine in the treatment of dermatophytosis

In vitro interactions of itraconazole with caspofungin or terbinafine against Sporothrix globosa

Terbinafine Hydrochloride Combined with Itraconazole for Fungal Skin Diseases: A Randomized Controlled Trial.

Combination Therapy of Terbinafine and Fluconazole or Itraconazole in Mice Model with Systemic Infection Due to Fluconazole-resistant Strains of Candida Albicans

In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes

Antifungal Susceptibility Testing of Clinical Isolates of Candida Albicans to Terbinafine, Miconazole and Nystatin

Synergism of Caspofungin and Terbinafine Against Clinical and Environmental Isolates of Cryptococcus Neoformans